NCT05068102 - A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 3, 2022

Primary Completion Date

April 3, 2026

Study Completion Date

May 31, 2026

Conditions

Carcinoma, Squamous Cell of Head and Neck (HNSCC)MelanomaNon-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

BI 765063

DRUG

Ezabenlimab

DRUG

[89Zr]Zr- BI 765063

\[89Zr\]Zr- BI 765063, specifically radiolabelled for immune-Positron Emission Tomography (PET)

DRUG

BI 770371

DRUG

[89Zr]Zr- BI 770371

\[89Zr\]Zr- BI 770371, specifically radiolabelled for immune-PET

Trial Locations (1)

RECRUITING

VU University Medical Center, Amsterdam